Julio C. Chávez

机构：Jacksonville College, Moffitt Cancer Center, Mayo Clinic in Arizona, Mayo Clinic in Florida · ORCID：0000-0002-2045-6238

发表论文 618 篇 · 总被引 20766 次 · h-index 54

代表论文

• Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study (2026 · Blood · 被引 4)
• Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma (2026 · Blood · 被引 4)
• Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update (2025 · Blood · 被引 4)
• CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies (2025 · Blood · 被引 2)
• Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study (2025 · Blood · 被引 1)
• Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (2025 · Blood · 被引 1)